US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Judge orders man accused of opening fire outside Wrigley Field held without bail
CHICAGO (AP) — A federal magistrate judge on Monday ordered a man accused of opening fire on a busy2024-05-22Major bridge in Baltimore, US collapses after being struck by cargo ship
The Key Bridge crumples after being struck by a ship, which is visible in the left of the frame. Pho2024-05-22People turning up drunk at emergency departments increasingly older
Lead author Dr Laura Joyce says excess alcohol consumption is a growing problem for EDs, accounting2024-05-22Sale continues dominant run as Braves beat Padres 3
ATLANTA (AP) — Chris Sale allowed only five hits in seven innings to continue his strong run and the2024-05-22Iniesta says he faced double taxation, asks for a settlement
Spanish soccer star Andres Iniesta requested a settlement of a tax row with Japanese authorities who2024-05-22
atest comment